Skip to main content

Agilent Technologies company profile

  • A · NYSE
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$173.96+0.55%Close 13 Nov 2026 · Market value $48.72B · Next results 23 Nov 2026

About Agilent Technologies

Agilent Technologies, Inc. is a company that provides application-focused solutions for the laboratory workflow, including instruments, software, services and consumables. Its operations are organized into three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography and mass spectrometry instruments, cell analysis, pathology solutions, genomics, biomolecular analysis and specialty contract development and manufacturing services for oligonucleotide-based therapeutics. Agilent CrossLab provides services, consumables, software and laboratory automation. Applied Markets provides gas chromatography, spectroscopy, vacuum and other instruments. Customers include pharmaceutical and biopharmaceutical companies, diagnostics and clinical laboratories, academic and government institutions, and companies in chemicals, food, environmental and forensics markets. Products are sold primarily through direct sales, supplemented by distributors and resellers.

A summary of the business section of the company's latest annual report, filed 22 Dec 2025.

Company facts

TickerA · NYSE
SectorInstruments
IndustryLife Sciences Tools & Services
IndexS&P 500
Fiscal year ends31 October
Reporting currencyUSD
CIK1090872
Latest annual report10-K, filed 22 Dec 2025

Officers and directors

NameRoleShares ownedLatest Form 4
Robert W. McMahonSr. VP and CFO117K · < 1%Shares withheld for tax, 22 May 2025
Koh Boon HweeDirector61.6K · < 1%Grant or award, 19 Mar 2026
Padraig McDonnellPresident and CEO · Director54.6K · < 1%Shares withheld for tax, 3 Jun 2026
George A. Scangos, PhDDirector38.5K · < 1%Grant or award, 19 Mar 2026
Daniel K. Podolsky, M.D.Director36.0K · < 1%Grant or award, 19 Mar 2026
Rodney GonsalvesV.P., Corporate Controller32.5K · < 1%Shares withheld for tax, 21 Nov 2025
Angelica RiemannSenior Vice President30.5K · < 1%Shares withheld for tax, 27 Feb 2026
Sue H. RatajDirector21.5K · < 1%Grant or award, 19 Mar 2026
Dow R. WilsonDirector18.2K · < 1%Grant or award, 19 Mar 2026
Mala AnandDirector14.5K · < 1%Grant or award, 19 Mar 2026
Otis Brawley, M.D.Director10.8K · < 1%Grant or award, 19 Mar 2026
Simon MaySenior Vice President7.1K · < 1%Shares withheld for tax, 8 May 2026
Bret DiMarcoSenior Vice President5.1K · < 1%Shares withheld for tax, 26 Nov 2025
Mikael Dolsten, M.D., PhDDirector5.0K · < 1%Open-market sale, 4 Sep 2026
Judy Gawlik BrownDirector1.7K · < 1%Grant or award, 19 Mar 2026
Pascal SoriotDirector1.2K · < 1%Shares withheld for tax, 19 Mar 2026
Boehnlein Glenn SDirector—Grant or award, 8 Sep 2026
KIRKWOOD JONAH PREVOSTSenior Vice President—Shares withheld for tax, 26 Jun 2026
Buckner Michael StevenSenior Vice President—Grant or award, 19 May 2026
Henson MeghanSenior Vice President—Shares withheld for tax, 31 Mar 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

A in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.